Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00992121 | An Open-Label Pharmacodynamic Study of Bevacivumab and Pazopanib in Renal Cell Carcinoma | PHASE1 | COMPLETED | 11 | — | — | Nov 18, 2009 | Nov 1, 2013 | Nov 13, 2017 | 1 | United Kingdom |
| Arm | Type | Description |
|---|---|---|
| Part I and 2 week dosing Part II | OTHER | Part I - bevacizumab 3 infusions at 2 week intervals Part II - pazopanib dosing 2 weeks in 3-week cycles |
| Part I and 3 week dosing Part II | OTHER | Part I - bevacizumab 3 infusions at 2 week interval, Part II - pazopanib dosing 3 weeks in 3-week cycles |
| Name | Type | Description |
|---|---|---|
| Bevacizumab | DRUG | Bevacizumab - 3 infusions of 10mg/kg administered at 2 week intervals - Part I |
| Pazopanib 2 week | DRUG | Pazopanib for first 2 weeks of each 3-week cycles as follows: 1) 200 mg twice weekly, 2) 200 mg every other day, 3) 200 mg qd, 4) 400 mg qd, 5) 800 mg qd, and 6) 1200 mg qd (Group 1). Maintenance pazopanib 800 mg qd for all 3 weeks throughout repeating 3-week cycles. Number of cycles: until death, loss of clinical benefit, unacceptable toxicity, or withdrawal from the study for other reasons. |
| Pazopanib 3 week | DRUG | Pazopanib throughout each 3-week cycle as follows: 1) 200 mg twice weekly, 2) 200 mg every other day, 3) 200 mg qd, 4) 400 mg qd, 5) 800 mg qd, and 6) 1200 mg qd (Group 1). Maintenance pazopanib 800 mg qd for all 3 weeks throughout repeating 3-week cycles. Number of cycles: until death, loss of clinical benefit, unacceptable toxicity, or withdrawal from the study for other reasons. |
Inclusion Criteria: * Histologically (any histological subtype) or cytologically confirmed unresectable RCC with a clear cell component. * Experienced documented evidence of radiological progression based on Response Evaluation Criteria in Solid Tumors \[RECIST\] while on first line (or greater) RC...